US EditionBoston Scientific gets Medicare reimbursement for Agent DCB
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Boston Scientific gets Medicare reimbursement for Agent DCB
The Agent drug-coated balloon. [Image from Boston Scientific] Boston Scientific (NYSE: BSX) announced today that CMS granted reimbursement for its Agent drug-coated balloon (DCB). CMS granted a new technology add-on payment (NTAP) for eligible cases using Agent. NTAP provides additional reimbursement to hospitals that use designated new medical technologies in the first few years of market introduction. Starting Oct. 1, 2025, CMS intends to prov…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
